Summary
The episode works through what placebo-controlled trials can show about the therapy component of psychedelic-assisted therapy, using a hypothetical four-arm design to show how the drug's estimated effect depends on the therapy given with it. Sarah and Kiffer calculate clinician hours for a hypothetical protocol that combines individual dosing with group integration, and they explain why the staffing of dosing sessions sets a floor on clinician time. They then test a touch agreement made while sober on several moments in a hypothetical session, sort invented integration notes into expected waves and reasons for referral, and set out, as general legal information, why preparation connected to a planned unauthorized use of psilocybin may carry legal risk in Canada. The hosts close by debating whether a cognitive behavioural approach should be the default therapy in psychedelic-assisted treatment.